Literature DB >> 1620650

The levels and biologic action of the human neutrophil granule peptide HP-1 in lung tumors.

A Bateman1, A Singh, S Jothy, R Fraser, F Esch, S Solomon.   

Abstract

HP-1 is the most abundant human representative of a recently discovered class of neutrophil cystine- and arginine-rich peptides. These peptides have many potentially regulatory activities expressed at nanomolar concentrations. To establish the levels of HP-1 that can accumulate in human lung tumors and nondiseased lung fragments, tissues were extracted for their peptide content. The extracts were purified on reverse phase HPLC, and HP-1 and related peptides were identified by sequence analysis and their concentrations in the tissue quantitated by amino acid analysis. Immunohistochemistry was performed and strongly suggests that HP-1 is confined to granulocytes under most circumstances, and indicates that the levels of HP-1 measured in the tumors reflect the levels obtained when solid tissue is infiltrated by neutrophils. The maximum observed levels were 26 nanomoles per gram wet weight of tissue. Attempts were then made to correlate this level to the cytotoxic potential of HP-1 by performing in vitro cytotoxicity dose-response curves on several cell lines. Most cells were killed at between 1 and 8 microM, and the response depended on the growth conditions of the cells. The levels of HP-1 that accumulate in tumors can exceed the in vitro cytolytic concentrations. The levels are also considerably in excess of those required to exert in vitro regulatory actions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1620650     DOI: 10.1016/0196-9781(92)90152-s

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

Review 1.  Multifunctional antimicrobial peptides: therapeutic targets in several human diseases.

Authors:  Mohamed Zaiou
Journal:  J Mol Med (Berl)       Date:  2007-01-10       Impact factor: 4.599

2.  Oncogenic relevant defensins: expression pattern and proliferation characteristics of human tumor cell lines.

Authors:  Jochen Winter; Dominik Kraus; Jan Reckenbeil; Rainer Probstmeier
Journal:  Tumour Biol       Date:  2015-12-28

3.  Plasma human neutrophil proteins-1, -2, and -3 levels in patients with bladder cancer.

Authors:  Mustafa Gunes; Ilhan Gecit; Necip Pirincci; Ahu Sarbay Kemik; Sevim Purisa; Kadir Ceylan; Mehmet Aslan
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-26       Impact factor: 4.553

4.  Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation.

Authors:  Claudia A Müller; Jasmina Markovic-Lipkovski; Tatjana Klatt; Jutta Gamper; Gerold Schwarz; Hermann Beck; Martin Deeg; Hubert Kalbacher; Susanne Widmann; Johannes T Wessels; Volker Becker; Gerhard A Müller; Thomas Flad
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 5.  Oncolytic activities of host defense peptides.

Authors:  Sammy Al-Benna; Yechiel Shai; Frank Jacobsen; Lars Steinstraesser
Journal:  Int J Mol Sci       Date:  2011-11-16       Impact factor: 5.923

6.  Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study.

Authors:  Jakob Albrethsen; Rikke Bøgebo; Steen Gammeltoft; Jesper Olsen; Benny Winther; Hans Raskov
Journal:  BMC Cancer       Date:  2005-01-19       Impact factor: 4.430

7.  Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients.

Authors:  Eline Berghmans; Julie Jacobs; Christophe Deben; Christophe Hermans; Glenn Broeckx; Evelien Smits; Evelyne Maes; Jo Raskin; Patrick Pauwels; Geert Baggerman
Journal:  Cancers (Basel)       Date:  2020-04-02       Impact factor: 6.639

Review 8.  Defensins: A Double-Edged Sword in Host Immunity.

Authors:  Dan Xu; Wuyuan Lu
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

Review 9.  From antimicrobial to anticancer peptides. A review.

Authors:  Diana Gaspar; A Salomé Veiga; Miguel A R B Castanho
Journal:  Front Microbiol       Date:  2013-10-01       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.